

# Spotlight on Prostate Cancer

An estimated 313,780 new cases of prostate cancer were diagnosed in the U.S. in 2025, making it the second-most common type of cancer.

Prostate cancer has a 98% five-year survival rate, including a 100% rate when diagnosed at the localized stage.

Prostate cancer is most common among older men, age 65-plus. It is common in families with a history of prostate cancer, and men of Black descent.



## Our Impact on Prostate Cancer Research

We've funded

**49 grants totaling over \$13.4 million.**

V Foundation funded researchers, over their careers, have:

Received

**over 375 grants and  
\$7.34 billion in funding.**

Produced

**over 4,100  
publications.**

Worked on

**28 clinical  
trials.**

## V Foundation Funded Researchers – Proven Positive Impact

- **Andrew Hsieh, M.D.**, a 2015 V Scholar and 2018 V Scholar Plus recipient from Fred Hutchinson Cancer Center, focused his work on uncovering what may be driving tumor growth in aggressive, androgen receptor (AR)-deficient cancers.
- Dr. Hsieh zeroed in on gene regulation in these tumors and discovered the activity of a key player in gene regulation called eIF4e, which drives prostate cancer, specifically in AR-deficient tumors.
- This is a significant finding that helps to explain why patients may stop responding to AR-targeted therapies. Additionally, blocking eIF4E activity may be a good strategy for stopping tumor growth in these patients.
- This monumental discovery has led to the development of an eIF4E inhibitor called eFT-508 (or tomivosertib), which is in several clinical trials for multiple cancer types with Effector Therapeutics.
- This provides a new hope for treating aggressive prostate cancers previously resistant to therapy.



*Andrew Hsieh, M.D.,  
2015 V Scholar and  
2018 V Scholar Plus recipient*